HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ziegler, M. G. Articles by Enna, S. J. Search for Related Content PubMed PubMed Citation Articles by Ziegler, M. G. Articles by Enna, S. J.

Norepinephrine and gamma-aminobutyric acid in amyotrophic lateral sclerosis

Departments of Medicine and Pharmacology, University of Texas Medical Branch, Galveston, TX (Dr. Ziegler), the Division of Neurology, Johns Hopkins Medical School, Baltimore, MD (Dr. Brooks), the Laboratory of Clinical Science, National Institutes of Health, Bethesda, MD (Dr. Lake), the Division of Neurosurgery, University of Pennsylvania School of Medicine, Philadelphia, PA (Dr. Wood), and the Departments of Pharmacology, Neurobiology, and Anatomy, University of Texas Medical School at Houston, Houston, TX (Dr. Enna).

Patients with amyotrophic lateral sclerosis have increased levels of the neurotransmitter norepinephrine in blood and cerebrospinal fluid and depressed levels of the inhibitory neurotransmitter gamma-aminobutyric acid in cerebrospinal fluid. These neurochemical alterations are most marked in patients bedridden with advanced disease, appear interrelated, and lead to cardiovascular alterations in patients with amyotrophic lateral sclerosis.

Address reprint requests to Dr. Ziegler, Room 457 Gail Borden, University of Texas Medical Branch, Galveston, TX 77550.

Accepted for publication May 25, 1979.

Supported in part by NHLBI grant HL 21817, USPHS Research Career Development Award NS-00335 (S. J. E.) and grants from the Pharmaceutical Manufacturers Association, Huntington's Chorea Foundation, and Merck Sharp & Dohme.

This article has been cited by other articles:

				H. Mitsumoto, M. R. Hanson, and D. A. Chad Amyotrophic Lateral Sclerosis: Recent Advances in Pathogenesis and Therapeutic Trials Arch Neurol, February 1, 1988; 45(2): 189 - 202. [Abstract] [PDF]

				K. Belendiuk, G. W. Belendiuk, D. X. Freedman, and J. P. Antel Neurotransmitter Abnormalities in Patients With Motor Neuron Disease Arch Neurol, July 1, 1981; 38(7): 415 - 417. [Abstract] [PDF]

				C. Lake, H. Gullner, R. Polinsky, M. Ebert, M. Ziegler, and F. Bartter Essential hypertension: central and peripheral norepinephrine Science, February 27, 1981; 211(4485): 955 - 957. [Abstract] [PDF]